Andrew B Lassman1, Stephanie L Pugh1, Mark R Gilbert1, Kenneth D Aldape1, Sandrine Geinoz1, Jan H Beumer1, Susan M Christner1, Ritsuko Komaki1, Lisa M DeAngelis1, Rakesh Gaur1, Emad Youssef1, Henry Wagner1, Minhee Won1, Minesh P Mehta1. 1. Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York (A.B.L. current); Memorial Sloan Kettering Cancer Center, New York, New York (A.B.L. during accrual, L.M.D.); NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania (S.L.P., S.G., M.W); The University of Texas MD Anderson Cancer Center, Houston, Texas (M.R.G., K.D.A. during accrual; R.K.); Neuro-Oncology Branch, National Cancer Institute/National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (M.R.G. current); University of Toronto and Princess Margaret Cancer Centre, Toronto, Canada (K.D.A. current); Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania (J.H.B., S.M.C.); Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy Pittsburgh, Pennsylvania (J.H.B.); NCI Community Oncology Research Program - Kansas City, Prairie Village, Kansas (R.G.); Arizona Oncology Services Foundation, Tucson, Arizona (E.Y.); Penn State University and The Milton S. Hershey Medical Center, Hershey, Pennsylvania (H.W.); University of Maryland Medical Systems, Baltimore, Maryland (M.P.M.).
Abstract
BACKGROUND: We conducted a phase II trial to evaluate the efficacy of dasatinib, a multitargeted tyrosine kinase inhibitor, for adults with recurrent glioblastoma (GBM). METHODS: Eligibility requirements were Karnofsky performance status ≥ 60%; no concurrent hepatic enzyme-inducing anticonvulsants; prior treatment with surgery, radiotherapy, and temozolomide exclusively; and activation or overexpression of ≥ 2 putative dasatinib targets in GBM (ie, SRC, c-KIT, EPHA2, and PDGFR). Using a 2-stage design, 77 eligible participants (27 in stage 1, if favorable, and then 50 in stage 2) were needed to detect an absolute improvement in the proportion of patients either alive and progression-free patients at 6 months (6mPFS) or responding (any duration) from a historical 11% to 25%. RESULTS: A high rate of ineligibility (27%) to stage 1 precluded a powered assessment of efficacy, but there was also infrequent treatment-related toxicity at 100 mg twice daily. Therefore, the study was redesigned to allow intrapatient escalation by 50 mg daily every cycle as tolerated (stage 1B) before determining whether to proceed to stage 2. Escalation was tolerable in 10 of 17 (59%) participants evaluable for that endpoint; however, among all eligible patients (stages 1 and 1B, n = 50), there were no radiographic responses, median overall survival was 7.9 months, median PFS was 1.7 months, and the 6mPFS rate was 6%. The clinical benefit was insufficient to correlate tested biomarkers with efficacy. The trial was closed without proceeding to stage 2. CONCLUSIONS: Intraparticipant dose escalation was feasible, but dasatinib was ineffective in recurrent GBM. Clinical trials.gov identified. NCT00423735 (available at http://clinicaltrials.gov/ct2/show/NCT00423735).
BACKGROUND: We conducted a phase II trial to evaluate the efficacy of dasatinib, a multitargeted tyrosine kinase inhibitor, for adults with recurrent glioblastoma (GBM). METHODS: Eligibility requirements were Karnofsky performance status ≥ 60%; no concurrent hepatic enzyme-inducing anticonvulsants; prior treatment with surgery, radiotherapy, and temozolomide exclusively; and activation or overexpression of ≥ 2 putative dasatinib targets in GBM (ie, SRC, c-KIT, EPHA2, and PDGFR). Using a 2-stage design, 77 eligible participants (27 in stage 1, if favorable, and then 50 in stage 2) were needed to detect an absolute improvement in the proportion of patients either alive and progression-free patients at 6 months (6mPFS) or responding (any duration) from a historical 11% to 25%. RESULTS: A high rate of ineligibility (27%) to stage 1 precluded a powered assessment of efficacy, but there was also infrequent treatment-related toxicity at 100 mg twice daily. Therefore, the study was redesigned to allow intrapatient escalation by 50 mg daily every cycle as tolerated (stage 1B) before determining whether to proceed to stage 2. Escalation was tolerable in 10 of 17 (59%) participants evaluable for that endpoint; however, among all eligible patients (stages 1 and 1B, n = 50), there were no radiographic responses, median overall survival was 7.9 months, median PFS was 1.7 months, and the 6mPFS rate was 6%. The clinical benefit was insufficient to correlate tested biomarkers with efficacy. The trial was closed without proceeding to stage 2. CONCLUSIONS: Intraparticipant dose escalation was feasible, but dasatinib was ineffective in recurrent GBM. Clinical trials.gov identified. NCT00423735 (available at http://clinicaltrials.gov/ct2/show/NCT00423735).
Authors: Louis J Lombardo; Francis Y Lee; Ping Chen; Derek Norris; Joel C Barrish; Kamelia Behnia; Stephen Castaneda; Lyndon A M Cornelius; Jagabandhu Das; Arthur M Doweyko; Craig Fairchild; John T Hunt; Ivan Inigo; Kathy Johnston; Amrita Kamath; David Kan; Herbert Klei; Punit Marathe; Suhong Pang; Russell Peterson; Sidney Pitt; Gary L Schieven; Robert J Schmidt; John Tokarski; Mei-Li Wen; John Wityak; Robert M Borzilleri Journal: J Med Chem Date: 2004-12-30 Impact factor: 7.446
Authors: Sagar Agarwal; Rajendar K Mittapalli; David M Zellmer; Jose L Gallardo; Randy Donelson; Charlie Seiler; Stacy A Decker; Karen S Santacruz; Jenny L Pokorny; Jann N Sarkaria; William F Elmquist; John R Ohlfest Journal: Mol Cancer Ther Date: 2012-08-13 Impact factor: 6.261
Authors: Peter S Hammerman; Martin L Sos; Alex H Ramos; Chunxiao Xu; Amit Dutt; Wenjun Zhou; Lear E Brace; Brittany A Woods; Wenchu Lin; Jianming Zhang; Xianming Deng; Sang Min Lim; Stefanie Heynck; Martin Peifer; Jeffrey R Simard; Michael S Lawrence; Robert C Onofrio; Helga B Salvesen; Danila Seidel; Thomas Zander; Johannes M Heuckmann; Alex Soltermann; Holger Moch; Mirjam Koker; Frauke Leenders; Franziska Gabler; Silvia Querings; Sascha Ansén; Elisabeth Brambilla; Christian Brambilla; Philippe Lorimier; Odd Terje Brustugun; Aslaug Helland; Iver Petersen; Joachim H Clement; Harry Groen; Wim Timens; Hannie Sietsma; Erich Stoelben; Jürgen Wolf; David G Beer; Ming Sound Tsao; Megan Hanna; Charles Hatton; Michael J Eck; Pasi A Janne; Bruce E Johnson; Wendy Winckler; Heidi Greulich; Adam J Bass; Jeonghee Cho; Daniel Rauh; Nathanael S Gray; Kwok-Kin Wong; Eric B Haura; Roman K Thomas; Matthew Meyerson Journal: Cancer Discov Date: 2011-06 Impact factor: 39.397
Authors: Enrico Franceschi; Roger Stupp; Martin J van den Bent; Carla van Herpen; Florence Laigle Donadey; Thierry Gorlia; Monika Hegi; Benoit Lhermitte; Lewis C Strauss; Anouk Allgeier; Denis Lacombe; Alba A Brandes Journal: Neuro Oncol Date: 2012-10-22 Impact factor: 12.300
Authors: Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245
Authors: Eric Raymond; Alba A Brandes; Christian Dittrich; Pierre Fumoleau; Bruno Coudert; Paul M J Clement; Marc Frenay; Roy Rampling; Roger Stupp; Johan M Kros; Michael C Heinrich; Thierry Gorlia; Denis Lacombe; Martin J van den Bent Journal: J Clin Oncol Date: 2008-10-01 Impact factor: 44.544
Authors: George D Demetri; Patricia Lo Russo; Iain R J MacPherson; Ding Wang; Jeffrey A Morgan; Valerie G Brunton; Prashni Paliwal; Shruti Agrawal; Maurizio Voi; T R Jeffry Evans Journal: Clin Cancer Res Date: 2009-09-29 Impact factor: 12.531
Authors: Eudocia C Quant; Andrew D Norden; Jan Drappatz; Alona Muzikansky; Lisa Doherty; Debra Lafrankie; Abigail Ciampa; Santosh Kesari; Patrick Y Wen Journal: Neuro Oncol Date: 2009-03-30 Impact factor: 12.300
Authors: Zachary Miklja; Viveka Nand Yadav; Rodrigo T Cartaxo; Ruby Siada; Chase C Thomas; Jessica R Cummings; Brendan Mullan; Stefanie Stallard; Alyssa Paul; Amy K Bruzek; Kyle Wierzbicki; Tao Yang; Taylor Garcia; Ian Wolfe; Marcia Leonard; Patricia L Robertson; Hugh Jl Garton; Daniel R Wahl; Hemant Parmar; Jann N Sarkaria; Cassie Kline; Sabine Mueller; Theodore Nicolaides; Chana Glasser; Sarah Es Leary; Sriram Venneti; Chandan Kumar-Sinha; Arul M Chinnaiyan; Rajen Mody; Manjunath P Pai; Timothy N Phoenix; Bernard L Marini; Carl Koschmann Journal: J Clin Invest Date: 2020-10-01 Impact factor: 14.808
Authors: Michael J Ciesielski; Yahao Bu; Stephan A Munich; Paola Teegarden; Michael P Smolinski; James L Clements; Johnson Y N Lau; David G Hangauer; Robert A Fenstermaker Journal: J Neurooncol Date: 2018-09-20 Impact factor: 4.130
Authors: Evanthia Galanis; S Keith Anderson; Erin L Twohy; Xiomara W Carrero; Jesse G Dixon; David Dinh Tran; Suriya A Jeyapalan; Daniel M Anderson; Timothy J Kaufmann; Ryan W Feathers; Caterina Giannini; Jan C Buckner; Panos Z Anastasiadis; David Schiff Journal: Cancer Date: 2019-07-10 Impact factor: 6.860
Authors: Zilai Wang; Daochun Sun; Yu-Jung Chen; Xuanhua Xie; Yufeng Shi; Viviane Tabar; Cameron W Brennan; Tejus A Bale; Chenura D Jayewickreme; Dan R Laks; Sheila Alcantara Llaguno; Luis F Parada Journal: Cancer Cell Date: 2020-07-09 Impact factor: 31.743
Authors: Enrico Franceschi; Roger Stupp; Martin J van den Bent; Carla van Herpen; Florence Laigle Donadey; Thierry Gorlia; Monika Hegi; Benoit Lhermitte; Lewis C Strauss; Anouk Allgeier; Denis Lacombe; Alba A Brandes Journal: Neuro Oncol Date: 2012-10-22 Impact factor: 12.300
Authors: Tracy T Batchelor; Elizabeth R Gerstner; Xiaobu Ye; Serena Desideri; Daniel G Duda; David Peereboom; Glenn J Lesser; Sajeel Chowdhary; Patrick Y Wen; Stuart Grossman; Jeffrey G Supko Journal: Neuro Oncol Date: 2017-04-01 Impact factor: 12.300